Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook ...

Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to-earnings-to-growth (PEG) ratio of 0.4. PEGs below 1 are generally ...

However, the stock took a hit after Eli Lilly lowered its full-year earnings outlook, attributing this to a $1.57 billion charge from acquiring an oral cancer drug from Scorpion Therapeutics.

Michael Nagle / Bloomberg via Getty Images Shares of Eli Lilly (LLY ... of the $2.33 billion consensus. Revenue Outlook Affirmed, Profit Forecasts Cut Lilly affirmed its full-year revenue guidance ...

The company also raised its full-year outlook, and the stock rallied over 15% since it reported the Q2 numbers. In this note, we discuss Eli Lilly’s stock performance, key takeaways from its ...

Price Targets: Delving into movements, analysts provide estimates for the future value of Eli Lilly and Co's stock. This analysis reveals shifts in analysts' expectations over time. For valuable ...

Eli Lilly (NYSE: LLY) stock has been a winner for investors of ... Eli Lilly increased its 2024 total revenue outlook by $2 billion to a range of $42.4 billion-$43.6 billion, owing to strong ...

This tepid outlook adds to concerns ... in late October last year, Eli Lilly shares have consolidated within a textbook symmetrical triangle. On Tuesday, the stock staged a decisive breakdown ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential ... so on that basis, the stock is very inexpensive. The GLP-1 market continues ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...